Efficacy and safety of neoadjuvant apatinib in combination with dose-dense paclitaxel and carboplatin in locally advanced triple negative breast cancer patients
10.3760/cma.j.cn112152-20200224-00122
- VernacularTitle:阿帕替尼联合紫杉醇和卡铂密集方案新辅助治疗三阴性乳腺癌的近期疗效及安全性
- Author:
Kaiping OU
1
;
Qiao LI
;
Yang LUO
;
Jianhong LYU
;
Hua ZHOU
;
Yang YANG
;
Youju CAI
;
Zijing WANG
;
Xin WANG
;
Liqiang QI
;
Fei MA
;
Binghe XU
Author Information
1. 北京市朝阳区三环肿瘤医院内科 100122
- Keywords:
Neoadjuvant chemotherapy;
Breast neoplasms;
Triple negative;
Apatinib
- From:
Chinese Journal of Oncology
2020;42(11):966-971
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the short-term efficacy and safety of apatinib in combination with dose-dense paclitaxel and carboplatin in locally advanced triple-negative breast cancer (TNBC) patients.Methods:From September 2018 to September 2019, 17 stage Ⅱ/Ⅲ TNBC patients were enrolled in this single arm, single center prospective phase Ⅱ study. They received neoadjuvant treatment of apatinib 250 mg per day, paclitaxel 175 mg/m 2 on 1 st day and a dose of carboplatin according to the area under curve (AUC)=4 on 2 nd day, every 14 days as a cycle. Results:By January 2020, 16 cases completed 4-7 cycles of apatinib treatment and 4-8 cycles of chemotherapy. The median cycles of apatinib treatment and chemotherapy were 5 cycles and 6 cycles, respectively. Two cases achieved complete responses (CR), 12 achieved partial responses (PR), 2 achieved stable diseases (SD) and no progressive disease was observed. The objective response rate (ORR) was 87.5%, disease control rate (DCR) was 100%. By January 2020, among 12 patients who received surgery, 8 achieved pathologic complete response (pCR, 66.7%). The grade Ⅲ/Ⅳ adverse events included: neutropenia, thrombocytopenia in 3 cases (18.8%) each, anemia, fatigue, arrhythmia and alanine aminotransferase (ALT) elevation in 1 case each. Apatinib was interrupted in 5 cases, and was discontinued in 3 cases; chemotherapy dosage was reduced in 1 case.Conclusion:Apatinib in combination with dose-dense paclitaxel and carboplatin neoadjuvant therapy are effective and well tolerated in locally advanced TNBC patients.
